Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares hit a new 52-week low on Tuesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 26059 shares trading hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Price Performance
The business’s 50 day moving average price is C$0.01 and its two-hundred day moving average price is C$0.01. The stock has a market cap of C$1.33 million, a P/E ratio of -1.00 and a beta of -0.02. The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Articles
- Five stocks we like better than Aequus Pharmaceuticals
- How to Invest in Small Cap Stocks
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- How to trade using analyst ratings
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Are Penny Stocks a Good Fit for Your Portfolio?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
